Previous Article | Next Article ![]()
Molecular and Cellular Biology, December 2004, p. 10289-10299, Vol. 24, No. 23
0270-7306/04/$08.00+0 DOI: 10.1128/MCB.24.23.10289-10299.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Zachary T. Schafer,1,
Jessica S. Tashker,1
Malia B. Potts,2
Mohanish Deshmukh,2 and
Sally Kornbluth1*
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham,1 Neuroscience Center, University of North Carolina, Chapel Hill, North Carolina2
Received 28 June 2004/ Returned for modification 11 August 2004/ Accepted 9 September 2004
Bcr-Abl, activated in chronic myelogenous leukemias, is a potent cell death inhibitor. Previous reports have shown that Bcr-Abl prevents apoptosis through inhibition of mitochondrial cytochrome c release. We report here that Bcr-Abl also inhibits caspase activation after the release of cytochrome c. Bcr-Abl inhibited caspase activation by cytochrome c added to cell-free lysates and prevented apoptosis when cytochrome c was microinjected into intact cells. Bcr-Abl acted posttranslationally to prevent the cytochrome c-induced binding of Apaf-1 to procaspase 9. Although Bcr-Abl prevented interaction of endogenous Apaf-1 with the recombinant prodomain of caspase 9, it did not affect the association of endogenous caspase 9 with the isolated Apaf-1 caspase recruitment domain (CARD) or Apaf-1 lacking WD-40 repeats. These data suggest that Apaf-1 recruitment of caspase 9 is faulty in the presence of Bcr-Abl and that cytochrome c/dATP-induced exposure of the Apaf-1 CARD is likely defective. These data provide a novel locus of Bcr-Abl antiapoptotic action and suggest a distinct mechanism of apoptosomal inhibition.
P.B.D. and Z.T.S. contributed equally to this work.
This article has been cited by other articles:
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»